PNLIP and neoplasm: The PTL nanocrystal delivery system, in combination with sorafenib (Sora), was used to treat tumors in mice with HCC, achieving a tumor inhibition rate of 81.86%, significantly higher than that of either PTL or Sora alone, indicating the combination’s ability to enhance the therapeutic effect while overcoming the poor water solubility of PTL (Liang et al., 2020).